Crossref
Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
JAMA · 12.11.2026 · e2623165
DOI: 10.1001/jama.2026.23165 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 12.11.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. JAMA, e2623165. https://doi.org/10.1001/jama.2026.23165
Vancouver
Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. JAMA. 2026:e2623165. doi:10.1001/jama.2026.23165
BibTeX
@article{euvimed2026,
title = {Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma},
journal = {JAMA},
year = {2026},
pages = {e2623165},
doi = {10.1001/jama.2026.23165}
}
EUVIMED